FDAnews
www.fdanews.com/articles/175733-soricimeds-ovarian-cancer-therapy-secures-orphan-drug-status

Soricimed’s Ovarian Cancer Therapy Secures Orphan Drug Status

March 14, 2016

Canadian drugmaker Soricimed Biopharma has secured orphan drug designation for its peptide SOR-C13 for treatment of ovarian cancer.

SOR-C13 targets TRPV6, a calcium channel prevalent in prostate, breast, lung and ovarian cancer.